While Trevi Therapeutics Inc has underperformed by -2.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TRVI rose by 66.50%, with highs and lows ranging from $7.48 to $2.36, whereas the simple moving average jumped by 44.10% in the last 200 days.
On July 01, 2025, Cantor Fitzgerald started tracking Trevi Therapeutics Inc (NASDAQ: TRVI) recommending Overweight. A report published by H.C. Wainwright on May 28, 2025, Initiated its previous ‘Buy’ rating for TRVI. Raymond James also Upgraded TRVI shares as ‘Strong Buy’, setting a target price of $29 on the company’s shares in a report dated March 10, 2025. Needham Reiterated the rating as Buy on March 10, 2025, but set its price target from $8 to $25. H.C. Wainwright resumed its ‘Buy’ rating for TRVI, as published in its report on December 12, 2024. Leerink Partners’s report from September 09, 2024 suggests a price prediction of $7 for TRVI shares, giving the stock a ‘Outperform’ rating. Raymond James also rated the stock as ‘Outperform’.
Analysis of Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -55.12% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 15.38, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and TRVI has an average volume of 1.71M. On a monthly basis, the volatility of the stock is set at 5.53%, whereas on a weekly basis, it is put at 6.16%, with a gain of 17.16% over the past seven days. Furthermore, long-term investors anticipate a median target price of $20.64, showing growth from the present price of $6.86, which can serve as yet another indication of whether TRVI is worth investing in or should be passed over.
How Do You Analyze Trevi Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 41.36%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 47.38% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TRVI shares are owned by institutional investors to the tune of 47.38% at present.
